Compare Aventis Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DIVIS LABORATORIES - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DIVIS LABORATORIES SANOFI INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 36.2 34.7 104.4% View Chart
P/BV x 6.3 6.7 95.3% View Chart
Dividend Yield % 1.4 0.9 149.7%  

Financials

 SANOFI INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
DIVIS LABORATORIES
Mar-19
SANOFI INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6,8401,639 417.3%   
Low Rs4,6301,115 415.2%   
Sales per share (Unadj.) Rs1,203.1186.3 645.7%  
Earnings per share (Unadj.) Rs165.351.0 324.3%  
Cash flow per share (Unadj.) Rs209.957.3 366.1%  
Dividends per share (Unadj.) Rs84.0016.00 525.0%  
Dividend yield (eoy) %1.51.2 126.1%  
Book value per share (Unadj.) Rs963.6261.8 368.1%  
Shares outstanding (eoy) m23.03265.47 8.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.87.4 64.5%   
Avg P/E ratio x34.727.0 128.4%  
P/CF ratio (eoy) x27.324.0 113.7%  
Price / Book Value ratio x6.05.3 113.1%  
Dividend payout %50.831.4 161.9%   
Avg Mkt Cap Rs m132,078365,592 36.1%   
No. of employees `0003.311.8 27.9%   
Total wages/salary Rs m4,0685,423 75.0%   
Avg. sales/employee Rs Th8,393.84,175.1 201.0%   
Avg. wages/employee Rs Th1,232.4457.7 269.2%   
Avg. net profit/employee Rs Th1,153.01,141.8 101.0%   
INCOME DATA
Net Sales Rs m27,70849,463 56.0%  
Other income Rs m8971,556 57.6%   
Total revenues Rs m28,60551,019 56.1%   
Gross profit Rs m6,23518,718 33.3%  
Depreciation Rs m1,0271,689 60.8%   
Interest Rs m735 20.0%   
Profit before tax Rs m6,09818,551 32.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2925,023 45.6%   
Profit after tax Rs m3,80613,527 28.1%  
Gross profit margin %22.537.8 59.5%  
Effective tax rate %37.627.1 138.8%   
Net profit margin %13.727.3 50.2%  
BALANCE SHEET DATA
Current assets Rs m15,92246,501 34.2%   
Current liabilities Rs m6,2358,468 73.6%   
Net working cap to sales %35.076.9 45.5%  
Current ratio x2.65.5 46.5%  
Inventory Days Days64131 48.7%  
Debtors Days Days2186 24.3%  
Net fixed assets Rs m7,53925,797 29.2%   
Share capital Rs m230531 43.3%   
"Free" reserves Rs m21,96268,962 31.8%   
Net worth Rs m22,19269,493 31.9%   
Long term debt Rs m00-   
Total assets Rs m29,83980,383 37.1%  
Interest coverage x872.1531.0 164.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 150.9%   
Return on assets %12.816.9 75.7%  
Return on equity %17.219.5 88.1%  
Return on capital %27.526.7 102.9%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m7,58741,238 18.4%   
Fx outflow Rs m7,14512,405 57.6%   
Net fx Rs m44228,833 1.5%   
CASH FLOW
From Operations Rs m3,7399,543 39.2%  
From Investments Rs m-731-6,854 10.7%  
From Financial Activity Rs m-1,972-2,459 80.2%  
Net Cashflow Rs m1,036230 451.2%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 11.8 122.0%  
FIIs % 14.6 19.0 76.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.2 61.0%  
Shareholders   15,184 31,796 47.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

DR. LAL PATHLABS LTD at All Time High; BSE HEALTHCARE Index Up 1.7% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

DR. LAL PATHLABS LTD share price has hit an all time high at Rs 1,550 (up 4.5%). The BSE HEALTHCARE Index is up by 1.7%. Among the top gainers in the BSE HEALTHCARE Index today are DR. LAL PATHLABS LTD (up 4.5%) and PFIZER (up 1.5%). The top losers include SANOFI INDIA and ABBOTT INDIA .

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Oct 22, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - SHASUN PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS